🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT07119593
Active, not recruiting Not applicable

Exercise Intensity

NCT07119593 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2025-09-22
Last updated
2026-04-29

Condition(s) studied

DialysisCardioprotection

Investigational drug(s) / intervention(s)

Intradialytic Cycling

Intradialytic Cycling: Intradialytic exercise has emerged as a safe and effective non-drug therapeutic approach to improve cardiovascular health and is now recommended for people undergoing hemodialysis treatment. Administration of a higher intensity exercise could offer better cardio-protective mechanisms and if the efficacy of cardiovascular protection is proven, it could be developed as a therapeutic option in the dialysis population.

Study summary

Patients receiving regular hemodialysis (HD) treatments are at a higher risk of cardiovascular events and death as HD can cause a decrease in the pumping of the heart during treatment called 'stunning'. Intradialytic exercise has emerged as a safe and effective non-drug approach to improve cardiovascular health and is now recommended for patients undergoing HD. It is currently advised that HD patients engage in at least 30 minutes of moderate to vigorous exercise three times per week. This study will evaluate the impact of exercise intensity in the HD population and determine if high impact exercise can offer better protection to the heart against HD-induced myocardial stunning.

Eligibility

Sex
ALL
Min age
18 Years
Max age
79 Years
Healthy volunteers
No
Inclusion Criteria: * Must be on chronic hemodialysis for at least 3 months * Age ≥ 18 years of age * Willing and able to provide informed consent Exclusion Criteria: * Regular vigorous exercise outside hemodialysis * \> 79 years of age * Intradialytic exercise in the past 3 months * Poor echogenicity * Acute coronary syndrome in the past 3 months * Unstable arrhythmia/angina * Shortness of breath at rest or with minimal activity * Symptomatic hypoglycemia (\>2x/week in the week prior to enrolment) * Symptomatic peripheral arterial disease * Unable or deemed unsafe to exercise for any reason * Severe musculoskeletal or orthopedic conditions * Aortic stenosis * Hypertrophic cardiopathy * Severe pulmonary hypertension * Symptomatic hypertension

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
London Health Sciences Centre London Ontario

More London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07119593 on ClinicalTrials.gov ↗ ← All trials in Canada